News

Irving, Texas-based Reata Pharmaceuticals, Inc. announced initial data from the LARIAT (A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension) trial (ClinicalTrials.gov Identifier: NCT02036970) evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients at the annual meeting of the 2015…

GlaxoSmithKline (GSK) recently announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has released a positive recommendation for its application to expand the existing therapeutic indication for pulmonary arterial hypertension (PAH) combination treatment Volibris® (ambrisentan) — a selective endothelin type-A receptor antagonist. The therapy is currently approved…

Obesity is a prevalent comorbidity of pulmonary arterial hypertension (PAH), according to a recent study that examined the presence of metabolic syndrome in patients with PAH. In fact, a large body of research has examined obesity-related PAH. However, patients with both of…

Actelion Ltd. announced that it will give poster presentation of results from the Phase III GRIPHON clinical trial of selexipag (Uptravi®). The presentation, to be held at the American College of Chest Physicians’ CHEST Congress in Montréal, Canada, will discuss safety and efficacy results of the investigational drug in pulmonary…

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent CTEPH in Wales now have access to Bayer’s therapy Adempas (riociguat) — a soluble guanylate cyclase (sGC) stimulator that works by relaxing blood vessels and increasing the supply of blood to the lungs, which helps reduce the workload of the heart. The All Wales Medicines…

In a new study, researchers have investigated the impact of cancer diagnosis on the prediction of right ventricular dysfunction (RVD) in acute pulmonary embolism (PE) patients using cardiac troponin I (cTnI). The study, entitled “Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular…

In a new study entitled “Signaling pathways underlying skeletal muscle wasting in experimental pulmonary arterial hypertension,” researchers investigated the potential mechanisms underlying patients with pulmonary arterial hypertension characteristic skeletal muscle abnormalities. The researchers identified that muscle loss is prompted by accumulation of dysfunctional mitochondrias and ineffective removal of damaged…

A recently published paper in Journal of Pathology and Translational Medicine entitled “Therapeutic Effects of Umbilical Cord Blood Derived Mesenchymal Stem Cell-Conditioned Medium on Pulmonary Arterial Hypertension in Rats” suggests that human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) may be useful…

A recent article suggests prostacyclin therapy, which is used for the treatment of pulmonary arterial hypertension (PAH), may also be useful for treating sarcoidosis-associated pulmonary hypertension (SAPH). PAH refers to high blood pressure of the lungs. The condition can occur as a result of several different diseases, including sarcoidosis; a disease…

Last year, a study entitled “T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension” published in the Chest journal associated the increased activity of a T-cell-mediated immune process — the T-helper 17 pathway — with Pulmonary Arterial Hypertension (PAH). This research is now being contested by a group of researchers…

In a world where vasodilators rule the landscape of treatments for pulmonary arterial hypertension (PAH), scientific research groups and pharmaceutical companies around the world are working to develop targeted therapeutics that focus on specific cellular pathways that are associated with dysfunction in PAH patients. Within the realm of targeted therapeutics,…

Researchers at the Yale Cardiovascular Research Center have identified a specialized cell type involved in pulmonary hypertension pathogenesis. The research paper, entitled “Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension,” was published in Science Translational Medicine. Pulmonary hypertension (PH) is a life-threatening…